Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI in previously treated RAS/BRAF wild-type metastatic colorectal cancer
ISRCTN39913423Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing Amivantamab + FOLFIRI with Cetuximab or bevacizumab + FOLFIRI (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Nov 2024; status: active, not recruiting.
02
Drugs
amivantamabcetuximabbevacizumabFOLFIRI
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ISRCTN39913423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN39913423.